Flow cytometry ""Ogata score"" for the diagnosis of myelodysplastic syndromes in a real-life setting. A Latin American experience

Imagem de Miniatura
Arquivos
art_MONTAUBAN_Flow_cytometry_Ogata_score_for_the_diagnosis_of_2019.PDF (618.78 KB)
Citações na Scopus
6
Tipo de produção
article
Data de publicação
2019
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY
Autores
MONTAUBAN, Sofia Grille
HERNANDEZ-PEREZ, Carlos R.
NOVOA, Viviana
LORAND-METZE, Irene
GONZALEZ, Jaqueline
SOLARI, Liliana
CISMONDI, Valeria
SERRANO, Juan Carlos
BURGNINI, Andreina
Citação
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, v.41, n.4, p.536-541, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Introduction Flow cytometry (FC) is a helpful tool for the diagnosis of myelodysplastic syndrome (MDS). Different FC score systems have been developed. The ""Ogata score"" is a simple diagnostic score that has been validated having a sensitivity of 69% and a specificity of 92% in low-risk MDS. We aimed to study the feasibility and the utility of the ""Ogata score"" for the diagnosis of MDS among Latin America (LA) Laboratories. Methods This is a case and control study conducted in LA institutions members of Grupo Latinoamericano de Mielodisplasia (GLAM). A total of 146 MDS patients and 57 control patients were included. ""Ogata score"" was calculated. Results The sensitivity of ""Ogata score"" was 75.6% (95% CI, 66.8-81.3), specificity was 91.2% (95% CI, 79.7-96.7), PPV was 95.6% (95% CI, 88.5-98.3), and NPV was 65.4% (95% CI, 49.1-71.9). In low/intermediate-1 IPSS patients group, the sensitivity was 70.1% (95% CI, 60.2-78.2), specificity was 91.2% (CI-95%, 79.7-96.7), PPV was 94.2% (95% CI, 86.4-97.8), and NPV was 62.1% (95% CI, 53.0-78.7). In the group of patients ""without MDS specific markers"" (patients without ring sideroblasts, blast excess, or chromosomal abnormalities), the sensitivity was 66.7% (CI-95%, 55.8-76.0), specificity was 91.2% (95% CI, 79.7-96.7), PPV was 92.3% (95% CI, 82.2-97.1), and NPV was 63.5% (95% CI, 51.9-73.5). Conclusions The diagnostic power found in this study was similar to the reported by Della-Porta et al. Also in LA, the analysis was made in modern equipment with acquisition of at least 100 000 events which permits a good reproducibility of the results.
Palavras-chave
diagnosis, flow cytometry, Latin America, myelodysplastic syndrome, Ogata score
URI
https://observatorio.fm.usp.br/handle/OPI/32988
Referências
  1. Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544
  2. Bardet V, 2015, HAEMATOLOGICA, V100, P475, DOI 10.3324/haematol.2014.112755
  3. Benesch Martin, 2004, Hematology, V9, P171, DOI 10.1080/10245330410001701521
  4. Bennett JM, 2016, CL LYMPH MYELOM LEUK, V16, P607, DOI 10.1016/j.clml.2016.08.005
  5. Bento LC, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00270
  6. Campo E, 2011, BLOOD, V117, P5019, DOI 10.1182/blood-2011-01-293050
  7. Cremers EMP, 2017, HAEMATOLOGICA, V102, P320, DOI 10.3324/haematol.2016.147843
  8. Della Porta MG, 2012, HAEMATOL-HEMATOL J, V97, P1209, DOI 10.3324/haematol.2011.048421
  9. Duetz C, 2018, PATHOBIOLOGY, V85, P274
  10. Greenberg P, 1997, BLOOD, V89, P2079
  11. Greenberg PL, 2012, BLOOD, V120, P2454, DOI 10.1182/blood-2012-03-420489
  12. Karai B, 2017, INT J LAB HEMATOL, V39, P577, DOI 10.1111/ijlh.12700
  13. Karai B, 2018, BIOCHEM MEDICA, V28, DOI 10.11613/BM.2018.020704
  14. Kern W, 2010, CANCER-AM CANCER SOC, V116, P4549, DOI 10.1002/cncr.25353
  15. Lorand-Metze I, 2007, LEUKEMIA RES, V31, P147, DOI 10.1016/j.leukres.2006.04.010
  16. MASCHEK H, 1993, ANN HEMATOL, V66, P117, DOI 10.1007/BF01697619
  17. Matarraz S, 2010, CYTOM PART B-CLIN CY, V78B, P154, DOI 10.1002/cyto.b.20513
  18. Mathis S, 2013, LEUKEMIA, V27, P1981, DOI 10.1038/leu.2013.178
  19. Metze K, 2016, CELL IMMUNOL, V310, P212, DOI 10.1016/j.cellimm.2016.09.008
  20. Monaghan SA, 2012, CYTOM PART B-CLIN CY, V82B, P217, DOI 10.1002/cyto.b.21016
  21. Ogata K, 2006, BLOOD, V108, P1037, DOI 10.1182/blood-2005-12-4916
  22. Ogata K, 2018, LEUKEMIA RES, V71, P75, DOI 10.1016/j.leukres.2018.07.009
  23. Ogata K, 2009, HAEMATOL-HEMATOL J, V94, P1066, DOI 10.3324/haematol.2009.008532
  24. Porwit A, 2014, LEUKEMIA, V28, P1793, DOI 10.1038/leu.2014.191
  25. Reis-Alves SC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081048
  26. Scott BL, 2008, BLOOD, V112, P2681, DOI 10.1182/blood-2008-05-153700
  27. Thiede C, 2016, FRONT ONCOL, V6
  28. Valent P, 2017, ONCOTARGET, V8, P73483, DOI 10.18632/oncotarget.19008
  29. van de Loosdrecht AA, 2009, HAEMATOL-HEMATOL J, V94, P1124, DOI 10.3324/haematol.2009.005801
  30. Wells DA, 2003, BLOOD, V102, P394, DOI 10.1182/blood-2002-09-2768
  31. Westers TM, 2012, LEUKEMIA, V26, P1730, DOI 10.1038/leu.2012.30
  32. Westers TM, 2017, HAEMATOLOGICA, V102, P308, DOI 10.3324/haematol.2016.147835
  33. Xu F, 2013, CYTOM PART B-CLIN CY, V84B, P267, DOI 10.1002/cyto.b.21089
  34. Xu F, 2010, BRIT J HAEMATOL, V149, P587, DOI 10.1111/j.1365-2141.2010.08146.x

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM